Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis
Author:
Funder
National Health and Medical Research Council of Australia
Cancer Institute NSW , Australia
Publisher
American Society for Clinical Investigation
Subject
General Medicine
Link
https://insight.jci.org/articles/view/157839/files/pdf
Reference54 articles.
1. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
2. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
3. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
4. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
5. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study;BMC Cancer;2024-06-14
2. Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer;American Journal of Clinical Pathology;2024-02-20
3. Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy;European Journal of Cancer;2024-02
4. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series;Journal for ImmunoTherapy of Cancer;2024-01
5. Monocyte-Related Markers as Predictors of Immune Checkpoint Inhibitor Efficacy and Immune-Related Adverse Events: A Systematic Review and Meta-Analysis;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3